Semaglutide by quarter
Coverage and results for Semaglutide quarter by quarter. Read the supplier-count column beside the median: a quarter where the compound mix changed is not comparable with the one before it, and the index cannot hold that constant retrospectively.
| Quarter | Batches | Reports | Median purity % | IQR pp | Suppliers | Flagged | What changed in the index |
|---|---|---|---|---|---|---|---|
| 2024-Q1 | 3 | 24 | 98.86 | 1.35 | 3 | 22 | Backfill quarter. Reports assayed earlier were accepted retrospectively where custody could be documented. |
| 2024-Q2 | 9 | 68 | 98.56 | 1.04 | 7 | 64 | First quarter of live submission. |
| 2024-Q3 | 8 | 80 | 98.73 | 1.20 | 6 | 80 | Nordanalyt Laboratories began contributing. |
| 2024-Q4 | 8 | 70 | 98.83 | 0.74 | 8 | 55 | Impurity-fingerprint matching introduced; first shared-bulk links published. |
| 2025-Q1 | 11 | 102 | 98.77 | 1.19 | 7 | 77 | Anomaly rule set expanded from seven rules to eleven. |
| 2025-Q2 | 7 | 45 | 99.02 | 1.40 | 5 | 34 | Gravimetric mass-balance reconciliation became mandatory on new records. |
| 2025-Q3 | 18 | 125 | 98.77 | 0.95 | 10 | 107 | Kestrel Bioanalytical began contributing; gradient-length normalisation introduced. |
| 2025-Q4 | 19 | 152 | 98.87 | 1.23 | 11 | 132 | Provenance classification became a required field. |
| 2026-Q1 | 14 | 79 | 98.96 | 0.81 | 7 | 73 | Rule AX-R12 added. Dataset v2 schema published. |
| 2026-Q2 | 15 | 96 | 99.20 | 0.88 | 8 | 90 | Buyer-sourced sensitivity analysis added to every supplier scorecard. |
| 2026-Q3 | 11 | 85 | 99.08 | 0.79 | 10 | 76 | Quarter in progress. Aggregates for this quarter are provisional. |
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes. A trend across 11 points, most of them thin, is a shape and not a finding.